Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewGenIvf Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewGenIvf Group's regulatory disclosures and financial reporting.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Limited registers the resale of up to 100,000,000 Class A Ordinary Shares to satisfy registration rights held by certain selling securityholders, including shares issuable to White Lion Capital and JAK Opportunities VI LLC pursuant to various note conversions and warrant exercises.
The prospectus states the company is not selling any shares here and will not receive resale proceeds; however, NewGenIvf may receive up to $500,000,000 from sales to White Lion under the White Lion Purchase Agreement, subject to conditions. The prospectus lists selling methods and distributions including brokerage, block trades, and underwritten offerings.
Key context: last reported close was $0.50 (reported March 12, 2026), outstanding shares were 2,273,790 Class A and 275 Class B as of March 12, 2026, and the company regained Nasdaq minimum bid-price compliance after reverse stock splits and received transfer approval to the Nasdaq Capital Market on February 27, 2025.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.
NewGenIvf Group Limited registers for the resale of up to 100,000,000 Class A Ordinary Shares by selling securityholders, constituting privately issued shares being registered for resale.
The prospectus states the Company is not selling these shares and will not receive proceeds from resale; it may, however, receive up to $500,000,000 under the White Lion Purchase Agreement subject to its terms. Shares outstanding were 2,273,790 Class A Ordinary Shares and 275 Class B Ordinary Shares as of March 2, 2026.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.
NewGenIvf Group Limited is implementing a one-for-five reverse stock split of its issued and unissued Class A Ordinary Shares. The reverse split will be effective at 12:01 a.m. (ET) on December 1, 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq the same day under the existing ticker NIVF.
The reverse split will reduce the number of outstanding Class A Ordinary Shares from 6,585,672 to approximately 1,317,135, so every five existing shares will be combined into one new share. No fractional shares will be issued; any shareholder who would otherwise receive a fraction will receive one whole post-split share instead. All outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amount by five, rounded to the nearest whole share.
NewGenIvf Group Limited approved a 1‑for‑5 reverse stock split to support compliance with Nasdaq’s minimum $1.00 bid price requirement. The company expects effectiveness on or around December 3, 2025, with Class A Ordinary Shares trading on a post‑split basis that day.
The action will reduce outstanding Class A Ordinary Shares from approximately 4,844,490 to approximately 968,898. Every five pre‑split Class A shares will automatically combine into one post‑split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole post‑split share at the participant level. Outstanding options, warrants and other convertibles will be adjusted by dividing the underlying share counts by five. No shareholder vote is required under BVI law, par value remains nil, and the authorized share amount is unlimited and unaffected.
NewGenIvf Group Limited announced a share repurchase program of up to US$2 million, as indicated in Exhibit 99.1 to a Form 6-K filing. Share repurchases can support shareholder value by decreasing the number of shares available in the market over time. The filing lists the program amount but does not include additional terms in this excerpt.